Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Corey

Showing results (171-180 of 222) with videos related to

Pageof 23
Sort By:
Biorxiv : the Preprint Server for Biology|March 30, 2023
GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behaviorAaqib M Bhat, Bhopal C Mohapatra, Haitao Luan, et al.
The Journal of Clinical Investigation|September 19, 2023
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer modelsSupreet Agarwal, Lei Fang, Kerry McGowen, et al.
Scientific Reports|June 12, 2024
GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behaviorAaqib M Bhat, Bhopal C Mohapatra, Haitao Luan, et al.
JCI Insight|December 8, 2021
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerNavonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, et al.
Nature Medicine|November 28, 2018
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axisMirja Rotinen, Sungyong You, Julie Yang, et al.
JCI Insight|March 16, 2021
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancerW Nathaniel Brennen, Yezi Zhu, Ilsa M Coleman, et al.
The Journal of Clinical Investigation|June 15, 2021
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growthMichael D Nyquist, Lisa S Ang, Alexandra Corella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation AnalysisJacob E Berchuck, Sylvan C Baca, Heather M McClure, et al.
Molecular Cancer Research : MCR|May 29, 2020
Targeting RET Kinase in Neuroendocrine Prostate CancerHalena R VanDeusen, Johnny R Ramroop, Katherine L Morel, et al.
Scientific Reports|November 7, 2022
The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancerFabio Quaglia, Shiv Ram Krishn, Khalid Sossey-Alaoui, et al.
Pageof 23

Showing results (171-180 of 222) with videos related to

Sort By:
Pageof 23
Biorxiv : the Preprint Server for Biology|March 30, 2023
GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behaviorAaqib M Bhat, Bhopal C Mohapatra, Haitao Luan, et al.
The Journal of Clinical Investigation|September 19, 2023
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer modelsSupreet Agarwal, Lei Fang, Kerry McGowen, et al.
Scientific Reports|June 12, 2024
GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behaviorAaqib M Bhat, Bhopal C Mohapatra, Haitao Luan, et al.
JCI Insight|December 8, 2021
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerNavonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, et al.
Nature Medicine|November 28, 2018
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axisMirja Rotinen, Sungyong You, Julie Yang, et al.
JCI Insight|March 16, 2021
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancerW Nathaniel Brennen, Yezi Zhu, Ilsa M Coleman, et al.
The Journal of Clinical Investigation|June 15, 2021
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growthMichael D Nyquist, Lisa S Ang, Alexandra Corella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation AnalysisJacob E Berchuck, Sylvan C Baca, Heather M McClure, et al.
Molecular Cancer Research : MCR|May 29, 2020
Targeting RET Kinase in Neuroendocrine Prostate CancerHalena R VanDeusen, Johnny R Ramroop, Katherine L Morel, et al.
Scientific Reports|November 7, 2022
The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancerFabio Quaglia, Shiv Ram Krishn, Khalid Sossey-Alaoui, et al.
Pageof 23